The ToGA trial demonstrated that trastuzumab therapy in combination with cytotoxic chemotherapy significantly improved survival of patients with human epidermal growth factor receptor 2 (HER2)-positive GC [3]. The gene discussed is ERBB2; the disease is gastric cancer.